This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levine, A.
Right arrow Articles by Dinari, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levine, A.
Right arrow Articles by Dinari, G.
Related Collections
Right arrow Heart & Blood Vessels
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 101 No. 3 March 1998, p. e9

ELECTRONIC ARTICLE:
QT Interval in Children and Infants Receiving Cisapride

Received Sep 29, 1997; accepted Nov 6, 1997.

Arie Levine, Rami Fogelman*, Leah SirotaDagger , Zili Zangen, Raanan Shamir, and Gabriel Dinari

From the Division of Gastroenterology and Nutrition, the Division of Cardiology* , and the Dagger  Neonatal Intensive Care Unit, Schneider Children's Medical Center of Israel, Tel Aviv University Sackler School of Medicine, Petah Tikva, Israel.

Objectives.  Life-threatening arrhythmias and prolonged QT interval have been reported in adults and children using cisapride, a medication structurally similar to procainamide. Premature infants have reduced activity of cytochrome p-450, the system responsible for metabolism of cisapride, which could lead to QT prolongation. Therefore, we prospectively studied premature infants and children receiving cisapride to analyze the effect of prolonged cisapride therapy on QT interval.

Design.  Premature infants in a neonatal intensive care unit and children seen at a pediatric gastroenterology clinic in a tertiary care hospital had electrocardiography-analyzed and -corrected QT interval measured before cisapride (0.8/mg/kg per day) therapy, and again after 1 month of therapy. If baseline electrocardiography was not performed initially, it was obtained after cessation of therapy.

Results.  A total of 30 children participated in the study. Mean corrected QT interval was similar at baseline and at 1 month after therapy. Significant QT prolongation was not found, and no adverse effects were recorded.

Conclusions.  Corrected QT interval during prolonged cisapride therapy at 0.8 mg/kg per day appears to be similar for premature infants and children. An inherent trend toward QT prolongation was not detected in either group. In the absence of other risk factors that alter cisapride metabolism or predispose to arrhythmia, cisapride may be safe for use in premature infants as well as in children. Additional studies are needed to confirm these data.

Key words: cisapride, arrhythmias, QT interval, prematurity, children.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
P. J. Salsberry and P. B. Reagan
Dynamics of Early Childhood Overweight
Pediatrics, December 1, 2005; 116(6): 1329 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Family IssuesHome page
J. Galtry and P. Callister
Assessing the Optimal Length of Parental Leave for Child and Parental Well-Being: How Can Research Inform Policy?
Journal of Family Issues, March 1, 2005; 26(2): 219 - 246.
[Abstract] [PDF]